Clinical Trials
40 trialsA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Eli Lilly and Company
ADGP
Second Affiliated Hospital, School of Medicine, Zhejiang University
ADTD
Second Affiliated Hospital, School of Medicine, Zhejiang University
ADDC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Helsinn Healthcare SA
Dexamethasone for Symptom Burden in Advanced Cancer Patients
M.D. Anderson Cancer Center
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
The Hospital for Sick Children
CAFCARS
British Columbia Cancer Agency
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
SWOG Cancer Research Network
ProTreat
University Hospital Freiburg
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
Duke University
A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer
Sichuan Cancer Hospital and Research Institute
OLNEPA
Instituto Brasileiro de Controle do Cancer
The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs
ChineseAMS
Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
Rafa Laboratories
GIM15-NEPA
Consorzio Oncotech
Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care
Khon Kaen University
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Wake Forest University Health Sciences
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Duke University
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
University of Washington
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
IRB 2003-551
University of Michigan Rogel Cancer Center
IVAC
Swedish Medical Center
Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting
Mashhad University of Medical Sciences
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Zhejiang University
Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy
University of Rochester
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
M.D. Anderson Cancer Center
Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients
Fraser Health
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
State University of New York - Upstate Medical University
Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
University of South Florida
Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting
Bharath Charitable Cancer Hospital and Institute
Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE
Fudan University
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
M.D. Anderson Cancer Center
ONO-7436 Phase II Study in Japan
Ono Pharmaceutical Co., Ltd.
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Northwestern University
RAD
Hallym University Medical Center
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
GlaxoSmithKline